This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Owen M. Wolkowitz, MD
Department of Psychiatry University of California, San Francisco San Francisco, CA 94143

Alan Breier, MD
Maryland Psychiatric Research Center Baltimore, MD 21228

Allen Doran, MD
Department of Psychiatry University of California, Davis Sacramento, CA 95817

John Kelsoe, MD; Steven M. Paul, MD; David Pickar, MD
National Institute of Mental Health Bethesda, MD 20892

Peter Lucas, MD
Veteran's Administration Medical Center Sepulveda, CA 91343

Arch Gen Psychiatry. 1989;46(11):1052-1053.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

Thienhaus and colleagues have raised several issues. To clarify the issue of baseline fluphenazine administration in our study, the number of capsules (active or placebo) was the same during the period of protocol participation for each patient. Since patients were unaware of when alprazolam was substituted, the possibility of a placebo response based on a new or increased capsule number was minimal or absent.

Thienhaus et al also questioned our choice of the BPRS as a measure of clinical change. While there are a number of scales that might have been appropriate in our study, the BPRS has been used effectively for over 25 Years.¹ It has high discriminant validity² and consists of clinically familiar symptoms and behavioral constructs that are suited to the level of abstraction and integration used by clinicians. Although its measure of psychopathology is somewhat global, we examined specific subscale scores (eg, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?